________________________________________________________________________________________________________________________________

(C) Qiagen 2010 - Michael CollasiusLaboratory Automation: Everyone Re-invents The Wheel

February 2010. The molecular diagnostics industry is aiming at automation of the screening process spanning over three core steps: sample preparation, analysis, and detection. The Achilles’ heel of laboratory instrument development is a persisting lack of interconnectivity or cross-company standards which demanding customers require.

However, divide et impera – divide customers, fragment markets they are in, and conquer these – big pharma customers are not anymore happy with such suppliers’ marketing strategies. Michael Collasius, Vice President Automated Systems Qiagen NV, discussed with B2Bioworld the issues. With an addendum by Peer Michael Schatz

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages
- Includes market data 2009 on the global in-vitro diagnostics market (segments incl. molecular diagnostics, turnover, CAGR) by Peer M. Schatz

Full Company License enquire here

Back to section

Related Editorial Articles

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, former Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Dr Leroy Hood, President Institute for Systems Biology, Seattle

Thermo Fisher’s BRIMS-Strategy Under Testing
Coping with Customers’ Response to Divide and Conquer Tactics of Mass Spec-Manufacturers

Boehringer Ingelheim: We are obliged to more and more move away from animal models
Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies

Electrophoresis in Proteomics
– Some Common Pitfalls and Smart Ways to Avoid Them

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

Synthetic Genomics:
Autochthon Biotechnology

Commercialisation Strategies for Functional Food, Feed and Biofuels from Algae by James Flatt, CTO Synthetic Genomics

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding by Johan Botterman, Head of Product Research Bayer CropScience

The Myriad Way
Peter D Meldrum, CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Handling Suppliers of Mass Spectrometers Delicately
Michael P. Myers, International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats

Resolving the Innovation Paradox
Günter von Au, Vice-Chairman of Board, Clariant AG

Instrument Standards: We need the users, and users have to adopt it
A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing by Oscar-Werner Reif, Member of Board Sartorius Stedim Biotech S.A.